Schenectady, NY, United States of America

Andrew A Burns

This inventor holds 16 USPTO granted patents and 4 published patent applications and 5 EPO patents, primarily in Holographic Storage. Top assignees: Cornell University, Sloan-Kettering Institute for Cancer Research, Sabic Innovative Plastics IP B.v.. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew A Burns. Retrieved from https://idiyas.com/inventor/andrew-a-burns

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16 

% Patents Active = 75.0

 

Average Co-Inventor Count = 5.7

ph-index = 6

Forward Citations = 1,509(Granted Patents)


Location History:

  • Ithaca, NY (US) (2011)
  • Niskayuna, NY (US) (2013 - 2022)
  • Schenectady, NY (US) (2014 - 2022)

Company Filing History:


Years Active: 2011-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Silica-Based Nanoparticles
Holographic Storage
Fluorescent Sensors
Medical Monitoring Devices
Photoluminescent Materials
Complex Holograms
Holographic Recording
Nanoparticle Applications
16 patents (USPTO):Explore Patents

Title: Innovations of Andrew A Burns in Nanotechnology

Introduction

Andrew A Burns is a prominent inventor based in Schenectady, NY (US), known for his significant contributions to the field of nanotechnology. With a total of 13 patents to his name, he has made remarkable advancements, particularly in the development of silica-based nanoparticles for medical applications.

Latest Patents

One of his latest patents focuses on multimodal silica-based nanoparticles. This invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring, and treatment of diseases such as cancer. The nanoparticle features a range of diameters, including between about 0.1 nm and about 100 nm, and is designed to have greater brightness and fluorescent quantum yield than free fluorescent compounds. Additionally, it exhibits high biostability and biocompatibility. To enhance urinary excretion, the nanoparticle may be coated with an organic polymer like poly(ethylene glycol) (PEG). The small size and silica base minimize toxicity when administered in vivo. Furthermore, the nanoparticle can be conjugated to a ligand for targeting specific cell types, such as tumor markers, and may also carry therapeutic agents. It is designed to be detectable by various imaging techniques, including positron emission tomography (PET) and magnetic resonance imaging (MRI), by incorporating radionuclides or paramagnetic ions.

Career Highlights

Throughout his career, Andrew A Burns has

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…